# Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

> **NCT00005812** · PHASE2 · TERMINATED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Brain Tumors
- Central Nervous System Tumors
- Leptomeningeal Metastases

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00005812
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-01
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** No objective response documented, protocol terminated after 12 patients.
- **Last updated:** 2013-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005812, "Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*